Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.
Tubiana
R
R
Gomard
E
E
Fleury
H
H
Gougeon
M L
ML
Mouthon
B
B
Picolet
H
H
Katlama
C
C
D018150:Avipoxvirus; D003257:Consumer Product Safety; D004311:Double-Blind Method; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000097:blood; D016655:HIV Core Protein p24 / Q000097:blood; D019302:HIV Envelope Protein gp160 / Q000235:genetics / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000276:immunology / Q000628:therapy* / Q000821:virology; D006801:Humans; D007125:Immunogenetics; D016233:Immunotherapy, Active; D011995:Recombination, Genetic; D014614:Vaccines, Synthetic; D019562:Viral Load; D014765:Viral Vaccines
C078788:ALVAC vaccine; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D019302:HIV Envelope Protein gp160; D014614:Vaccines, Synthetic; D014765:Viral Vaccines